Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a Comprehensive Analysis of Immunotherapy
Authors:
- 1 January 2023
- journal article
- research article
- Published by Begell House Inc. Publishers in Critical Reviews™ in Eukaryotic Gene Expression
- Vol. 33 (6) , 73-86
Abstract
As a newly discovered mechanism of cell death, disulfidptosis is expected to help diagnose and treat bladder cancer patients. First, data obtained from public databases were analyzed using bioinformatics techniques. SVA packages were used to combine data from different databases to remove batch effects. Then, the differential analysis and COX regression analysis of ten disulfidptosis-related genes identified four prognostically relevant differentially expressed genes which were subjected to Lasso regression for further screening to obtain model-related genes and output model formulas. The predictive power of the prognostic model was verified and the immunohistochemistry of model-related genes was verified in the HPA database. Pathway enrichment analysis was performed to identify the mechanism of bladder cancer development and progression. The tumor microenvironment and immune cell infiltration of bladder cancer patients with different risk scores were analyzed to personalize treatment. Then, information from the IMvigor210 database was used to predict the responsiveness of different risk patients to immunotherapy. The oncoPredict package was used to predict the sensitivity of patients at different risk to chemotherapy drugs, and its results have some reference value for guiding clinical use. After confirming that our model could reliably predict the prognosis of bladder cancer patients, the risk scores were combined with clinical information to create a nomogram to accurately calculate the patient survival rate. A prognostic model containing three disulfidptosis-related genes (NDUFA11, RPN1, SLC3A2) was constructed. The functional enrichment analysis and immune-related analysis indicated patients in the high-risk group were candidates for immunotherapy. The results of drug susceptibility analysis can guide more accurate treatment for bladder cancer patients and the nomogram can accurately predict patient survival. NDUFA11, RPN1, and SLC3A2 are potential novel biomarkers for the diagnosis and treatment of bladder cancer. The comprehensive analysis of tumor immune profiles indicated that patients in the high-risk group are expected to benefit from immunotherapy.Keywords
This publication has 35 references indexed in Scilit:
- Structure of the human LAT1–4F2hc heteromeric amino acid transporter complexNature, 2019
- Comparative Gene Expression Profiles in Parathyroid Adenoma and Normal Parathyroid TissueJournal of Clinical Medicine, 2019
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypesBritish Journal of Cancer, 2018
- The Drosophila TGF-beta/Activin-like ligands Dawdle and Myoglianin appear to modulate adult lifespan through regulation of 26S proteasome function in adult muscleBiology Open, 2018
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- CD98 marks a subpopulation of head and neck squamous cell carcinoma cells with stem cell propertiesStem Cell Research, 2013
- L‐type amino‐acid transporter 1 as a novel biomarker for high‐grade malignancy in prostate cancerPathology International, 2008
- The nuclear encoded subunits of complex I from bovine heart mitochondriaBiochimica et Biophysica Acta (BBA) - Bioenergetics, 2003
- Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell linesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2001